Apellis Pharmaceuticals (APLS) PT Raised to $46 at BofA Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts APLS Hot Sheet
Price: $41.03 --0%
Rating Summary:
6 Buy, 23 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Rating Summary:
6 Buy, 23 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Join SI Premium – FREE
BofA Securities analyst Tazeen Ahmad raised the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $46.00 (from $44.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Arista Networks (ANET) PT Raised to $261; Piper Sandler Reiterates 'Top Pick'
- Amgen (AMGN) PT Raised to $400 at Bernstein SocGen Group
- Waters Corp. (WAT) PT Raised to $535 at Bernstein SocGen Group
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
